TABLE 1.
Genotypic features of the glioma cell lines used in this study
IC50 concentrations for CDK inhibitors at 72 hours of treatment as determined by MTS assay.
| Cell Line | Genotypic Features |
CDK Inhibitors, IC50 (µM) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| TP53 | PTEN | P14 ARF | Dina | Ribo | Palbo | AZD5438 | AMG925 | ||
| 1 | U87 | Homo, WT/WT | Del | Del | 0.024 | >20 | >20 | 11.68 | 4.99 |
| 2 | LNZ308 | Hetero, del/translocated | Del | WT | 0.034 | >20 | >20 | 2.49 | 5.86 |
| 3 | A172 | Hetero, WT/WT | Del | Del | 0.020 | >20 | >10 | 2.93 | 7.87 |
| 4 | U373 | Homo, Mut273 | Mu | WT | 0.021 | >20 | >20 | 2.59 | 7.99 |
| 5 | LN229 | Hetero, WT/Mut164 | WT | Del | 0.041 | NT | NT | NT | NT |
| 6 | LN18 | Hetero, WT/Mut238 | WT | Del | 0.022 | >20 | 14.08 | 2.25 | 5.73 |
| 7 | T98G | Homo, Mut237 | Mut | Del | 0.514 | >20 | >20 | 14.36 | 12.33 |
Del, deleted; Dina, dinaciclib; Hetero, heterozygous; Homo, homozygous; Mut, mutant; NT, not tested; Pablo, palbociclib; Ribo, ribociclib; WT, wild-type.